(dtpa-phe(1))-octreotide and Endocrine-Gland-Neoplasms

(dtpa-phe(1))-octreotide has been researched along with Endocrine-Gland-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for (dtpa-phe(1))-octreotide and Endocrine-Gland-Neoplasms

ArticleYear
Human biodistribution of [111In]diethylenetriaminepentaacetic acid-(DTPA)-D-[Phe1]-octreotide and peroperative detection of endocrine tumors.
    Cancer research, 1995, Dec-01, Volume: 55, Issue:23 Suppl

    Requisites for preoperative and intraoperative tumor localization with [111In]diethylenetriaminepentaacetic acid-D-[Phe1]-octreotide scanning were explored in 23 patients with endocrine tumors (15 carcinoids, 4 insulinomas, and single cases of gastrinoma, medullary thyroid carcinoma, aldosteronoma, and paraganglioma). The patients were subjected to Octreoscan single photon emission computed tomographic examination prior to surgery and well counter investigation of nuclide uptake in tumors and normal tissues sampled at surgery. Somatostatin receptor-positive tumors demonstrated efficient nuclide accumulation with mean tumor:blood radioactivity ratios of 180-370 (for carcinoids and insulinoma), compared with tissue:blood ratios of 302 for spleen, 42 for liver, and < 10-15 in other normal tissues (pancreas, small intestine, and mesenteric fat). Inefficient preoperative visualization of lesions was related to inconspicuous size, as for primary intestinal carcinoids, tiny liver metastases, and a single small insulinoma. High background activity, pronounced tumor fibrosis, and meager accumulation of tracer also interfered with visualization. Tumor deposits in organs with low background activity (such as carcinoid mesenteric metastases and endocrine pancreatic tumors) were generally most readily detected. Intraoperative investigations with hand-held gamma detector probes were disturbed by obvious high background activity. These investigations revealed two preoperatively unrecognized primary intestinal carcinoids, which, however, were both palpable during surgery. These studies, therefore, had little impact on the surgical strategy.

    Topics: Adult; Aged; Child, Preschool; Endocrine Gland Neoplasms; Female; Humans; Indium Radioisotopes; Intraoperative Period; Male; Middle Aged; Octreotide; Pentetic Acid; Receptors, Somatostatin; Sensitivity and Specificity; Tissue Distribution; Tomography, Emission-Computed, Single-Photon

1995
Distribution and elimination of the somatostatin analogue (111In-DTPA-D-Phe1)-Octreotide (OctreoScan111).
    Acta oncologica (Stockholm, Sweden), 1993, Volume: 32, Issue:2

    The distribution and elimination characteristics of the 111In-labelled somatostatin analogue OctreoScan111 were studied in 23 patients with malignant tumours. The substance exhibited a rapid blood elimination following a bi-phasic pattern. The initial part of the elimination curves showed a t1/2a of between 0.27 and 3.6 h. The patients investigated had creatinine clearance rates ranging from 33 to 124 ml/min. However, within this range, no apparent correlation was found between the OctreoScan111 elimination rate and kidney function. Also no correlation was observed between the amount of administered activity and the elimination rate of OctreoScan111. The serum radioactivity of 6 patients was analyzed with respect to molecular size. These experiments showed that OctreoScan111 circulated unbound in serum. About 3% of the radioactivity, most probably representing 111In-chloride of DTPA-111In-chloride, circulated protein-bound. The elimination of OctreoScan111 radioactivity in urine displayed a bi-phasic pattern. Size separation of the radioactivity appearing in the urine after 24 h showed a higher molecular weight when compared with OctreoScan111, indicating the existence of a metabolite of the injected substance. The results obtained are discussed in the light of a potential role for the substance in systemic radiotherapy.

    Topics: Adenoma, Islet Cell; Adult; Aged; Carcinoid Tumor; Chromatography, Gel; Endocrine Gland Neoplasms; Female; Half-Life; Humans; Indium Radioisotopes; Kidney; Male; Middle Aged; Molecular Weight; Neoplasms; Octreotide; Pancreatic Neoplasms; Pentetic Acid; Thyroid Neoplasms

1993